HSBC Raises AbbVie Price Target to $315 on Immunology Drug Label Expansions
HSBC raised its price target for AbbVie (NYSE: ABBV) to $315, citing potential label expansions for Skyrizi and Rinvoq. The analyst expects earnings growth to accelerate, leading to a rerating of the shares. AbbVie trades at 16x forward earnings, below the S&P 500's multiple. The company is also acquiring Apogee Therapeutics for $10.9 billion. AbbVie's stock is up 17% year-to-date, with a 2.6% forward dividend yield.
How this was made
The 30-second read
Why it matters
The upgrade could drive short‑term buying interest and support a higher valuation multiple if the label expansions materialize.
Market read
Analyst target raises are a common catalyst for stock moves; this one signals potential upside for AbbVie and may influence peer valuations.
What to watch
Potential pricing pressure from biosimilars and the one‑time acquisition charge from Apogee may temper earnings growth.
Background
HSBC analyst Rajesh Kumar upgraded AbbVie with a new $315 price target, emphasizing upcoming label expansions for its immunology drugs Skyrizi and Rinvoq.
Ticker impact
HSBC raised its price target for AbbVie to $315, citing pending label expansions for Skyrizi and Rinvoq.
likely upward pressure as investors price in the higher target and potential rerating.
The new $315 target implies ~20% upside from current price and is based on concrete pipeline milestones.
Market effects
May lift sentiment in the broader immunology/pharma sector as label expansion expectations rise.
US biotech and pharma stocks could see modest gains.
Limited to investors tracking large‑cap pharma earnings and pipeline news.
Counterpoint
The target assumes successful label wins; regulatory setbacks or competition could limit upside.
Key entities
- companyAbbVie Inc.
US‑listed biopharma company (NYSE: ABBV).
- analyst_firmHSBC
Equity research house issuing the target raise.
